Neuland Labs shares surged 3% after the company announced a ₹342 crore capital expenditure plan aimed at bolstering its manufacturing capabilities to meet increasing market demand. The investment focuses on expanding peptide synthesis capacity at Unit 1 and adding significant capacity at Unit 3. As of 9:17 AM, the shares were trading 2.96% higher at Rs 13,612.45.
Unit 1 will see a major boost in peptide manufacturing capabilities, increasing capacity from 0.5 KL to 6.87 KL with an investment of ₹254 crore, funded through borrowings and internal accruals. This initiative underscores Neuland Labs’ commitment to scaling operations for CMS and GDS customers, with completion expected by FY27.
Additionally, Unit 3 will enhance its production capacity by 52 KL with an investment of ₹88 crore, funded internally, to address rising customer demand within 15-18 months.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
